Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Update

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 21,000 shares, a drop of 27.8% from the September 30th total of 29,100 shares. Approximately 0.7% of the company’s shares are sold short. Based on an average daily trading volume, of 510,200 shares, the short-interest ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. William Blair began coverage on Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock. StockNews.com began coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They set a “sell” rating on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday. Leerink Partners assumed coverage on shares of Tenax Therapeutics in a research report on Thursday. They set an “outperform” rating and a $16.00 price objective on the stock. Finally, Guggenheim started coverage on Tenax Therapeutics in a research note on Monday, October 14th. They issued a “buy” rating and a $16.00 target price for the company. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Tenax Therapeutics Stock Up 2.5 %

Shares of NASDAQ TENX traded up $0.12 during mid-day trading on Monday, reaching $4.87. 94,870 shares of the company’s stock traded hands, compared to its average volume of 276,528. The business has a 50-day simple moving average of $3.80 and a 200 day simple moving average of $3.59. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. On average, equities research analysts forecast that Tenax Therapeutics will post -6.62 EPS for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.